ADALAT LA 20 Milligram Tablet Prolonged Release

Country: Írland

Tungumál: enska

Heimild: HPRA (Health Products Regulatory Authority)

Kauptu það núna

Download Vara einkenni (SPC)
28-05-2024

Virkt innihaldsefni:

NIFEDIPINE

Fáanlegur frá:

B & S Healthcare

INN (Alþjóðlegt nafn):

NIFEDIPINE

Skammtar:

20 Milligram

Lyfjaform:

Tablet Prolonged Release

Gerð lyfseðils:

Product subject to prescription which may be renewed (B)

Leyfisstaða:

Authorised

Leyfisdagur:

0000-00-00

Upplýsingar fylgiseðill

                                PACKAGE LEAFLET - INFORMATION FOR THE USER 
 
ADALAT
® 
LA 20MG 
PROLONGED-RELEASE TABLETS 
(nifedipine) 
 
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU  
START TAKING THIS MEDICINE. 
 
Keep this leaflet. You may need to read it again. 
 
If you have more questions, ask your doctor or 
pharmacist. 
 
This medicine has been prescribed for you. 
 
Do not pass it on to others. It may harm them, even if 
their symptoms are the same as yours 
 
 
If any of the side effects gets serious, or if you notice any  
side effects not listed in this leaflet, please tell your doctor 
or pharmacist.
  
 
The name of your medicine is Adalat LA 20mg Prolonged-
release Tablets but it will be referred to as Adalat LA 
throughout this leaflet. 
 
IN THIS LEAFLET 
1.  What Adalat LA is 
2.  Before you take Adalat LA 
3.  How you take Adalat LA 
4.  Possible side effects 
5.  How to store Adalat LA 
6.  Further information 
 
1. WHAT ADALAT LA IS 
 
Adalat LA contains nifedipine, which belongs to a group of 
medicines called _calcium antagonists._ 
 
ADALAT LA IS USED TO TREAT HIGH BLOOD PRESSURE OR 
ANGINA _(chest pain). _
 
For high blood pressure: Adalat LA works by relaxing and 
expanding the blood vessels. This makes the blood flow 
more easily and lowers blood pressure. Lower blood 
pressure reduces the strain on your heart. 
 
For angina: Adalat LA works by relaxing and expanding the  
arteries supplying the heart. This allows more blood and 
oxygen to reach the heart and decreases the strain on it. 
Your angina attacks will be less severe and less frequent if 
there is less strain on the heart. 
 
2. BEFORE YOU TAKE ADALAT LA 
 
DO NOT TAKE ADALAT LA: 
 
•  IF YOU HAVE HAD A HEART ATTACK within the last 
month. 
 
•  IF YOU GET A SUDDEN ANGINA ATTACK. Adalat LA will 
not help relieve symptoms of angina quickly. 
 
•  IF YOU HAVE UNSTABLE ANG
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Adalat LA 20mg Prolonged-release Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged-release Film-coated tablet contains 20 mg nifedipine.
Excipients: Sodium
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Prolonged-release, film-coated tablet.
_Product imported from UK:_
Pink, circular biconvex tablets marked 'Adalat 20' with black ink on one side.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the treatment of mild to moderate hypertension.
For the management of chronic stable angina pectoris either as monotherapy or in combination with a beta-blocker.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
METHOD OF ADMINISTRATION
ORAL USE
As far as possible the treatment must be tailored to the needs of the individual.
Depending on the clinical picture in each case, the basic dose must be introduced gradually.
Unless otherwise prescribed, the following dosage guidelines apply for adults:
•
For CORONARY HEART DISEASE:
CHRONIC STABLE ANGINA PECTORIS (angina of effort)
1 Adalat LA 20 mg tablet once daily (1 x 20 mg/day)
•
For HYPERTENSION:
1 Adalat LA 20 mg tablet once daily (1 x 20 mg/day)
In general therapy should be initiated with 30 mg once daily.
Where registered a starting dose of 20 mg once daily may be considered when medically indicated. Interim doses i.e. 40
mg, 50 mg etc. can be applied by combinations of i.e. 20 mg + 20 mg or 20 mg + 30 mg tablets.
Depending on the severity of the disease and the patient's response the dose can be increased in stages up to 90 mg once
daily.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 26/09/2013_
_CRN 2129159_
_page number: 1_
Co-admi
                                
                                Lestu allt skjalið
                                
                            

Leitaðu viðvaranir sem tengjast þessari vöru